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Atypical natural killer T-cell receptor recognition of
CD1d–lipid antigens
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Crucial to Natural Killer T (NKT) cell function is the interaction between their T-cell receptor
(TCR) and CD1d-antigen complex. However, the diversity of the NKT cell repertoire and the
ensuing interactions with CD1d-antigen remain unclear. We describe an atypical population of
CD1d–a-galactosylceramide (a-GalCer)-reactive human NKT cells that differ markedly from
the prototypical TRAV10-TRAJ18-TRBV25-1þ type I NKT cell repertoire. These cells express
a range of TCR a- and b-chains that show differential recognition of glycolipid antigens. Two
atypical NKT TCRs (TRAV21-TRAJ8-TRBV7–8 and TRAV12-3-TRAJ27-TRBV6-5) bind
orthogonally over the A0-pocket of CD1d, adopting distinct docking modes that contrast with
the docking mode of all type I NKT TCR-CD1d-antigen complexes. Moreover, the interactions
with a-GalCer differ between the type I and these atypical NKT TCRs. Accordingly, diverse
NKT TCR repertoire usage manifests in varied docking strategies and speciﬁcities towards
CD1d–a-GalCer and related antigens, thus providing far greater scope for diverse glycolipid
antigen recognition.
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ab T cells can be activated by peptides, metabolitesand lipids when bound to their requisite antigen(Ag)-presenting molecules1–3. The CD1 family of
MHC-class I-like molecules present an array of endogenous and
foreign lipids Ags that are recognized by specialized T-cell
populations4,5. For example, NKT cells are activated by lipid-
based Ags presented by CD1d6. Based on ligand speciﬁcity and
ab TCR composition, NKT cells are broadly sub-divided into two
populations, type I and II. a-Galactosylceramide (a-GalCer) is the
prototypical Ag for type I NKT cells, which express an invariant
TCR a-chain (TRAV10þTRAJ18þ (Va24-Ja18) in humans and
the orthologous TRAV11þTRAJ18þ (Va14-Ja18) in mice)6–8.
While type II NKT cells display a diverse TCR repertoire, and
while their Ag-speciﬁcity remains unclear, they are nevertheless
characterized as being non-reactive towards a-GalCer6,9. The
apparent functional divergence between type I and type II NKT
cells arises, in part, from the interaction between the NKT TCR
and CD1d–Ag8.
Despite the prototypical type I NKT TCR gene usage,
variations within the CD1d–a-GalCer reactive repertoire exist
that subsequently impact on ligand speciﬁcity and functional
outcome. For example, while human type I NKT cells typically
use TRBV25-1 (Vb11)-encoded TCR b-chains, mouse type I
NKT cells can utilize TRBV13 (Vb8), TRBV29 (Vb7) and TRBV1
(Vb2) TCR b-chains, with the variations in the TRBV repertoire
impacting on the range of ligands a given NKT TCR can interact
with10–16. Similarly, both mouse and human NKT cells can utilize
alternative TCR a-chains that retains a-GalCer reactivity17–21.
For example, TRAV10TRAJ18þTRBV25-1þ NKT cells
comprise up to 15% of human CD1d–a-GalCer reactive NKT
cells17. Despite their comparable reactivity to a-GalCer and their
identical TRAJ18 usage, these cells appear to exhibit a lower
afﬁnity towards a-glucosylceramide (a-GlcCer) compared with
the TRAV10þTRAJ18þ type I NKT cells17. In contrast, mouse
TRAV13-3þTRAJ50þTRBV13þ (Va10þ Ja50þVb8þ ) CD1d–
a-GalCer reactive NKT cells exhibited a greater reactivity towards
a-GlcCer in comparison to a-GalCer, and they were selectively
reactive to a mycobacterial Ag a-glucuronosyldiacylglycerol19.
Moreover, a population of a-GalCer-reactive TRDV1þ (Vd1þ )
gd T cells was identiﬁed recently, and these cells also exhibited
a distinct lipid–Ag-binding proﬁle, thereby highlighting the
breadth of TCR usage that engenders CD1d–a-GalCer
recognition22. Therefore, if we are to fully understand the
signiﬁcance and therapeutic potential of CD1d–lipid Ag
recognition in the immune system, it is vital to understand how
variations within the NKT TCR repertoire impacts on CD1d–Ag
recognition.
The crystal structures of a large panel of human and
mouse type I NKT TCRs have been determined in complex
with CD1d presenting a broad repertoire of chemically
distinct lipids including synthetic ligands, self- and microbial
ligands10–12,15,19,20,23–34. Universally, despite the NKT cell
repertoire and antigenic variations, the resultant type I NKT
abTCR–CD1d–Ag complexes exhibit a highly conserved docking
strategy. Namely, the type I NKT TCR docks, in a parallel
manner, over the F0-pocket of CD1d8. Here the semi-invariant
type I NKT TCR a-chain dominated the interaction, binding
to CD1d and Ag, whereas the TCR b-chain ligated only to
CD1d. Nevertheless, within this consensus footprint, altered
contributions from the complementarity determining regions
(CDRs) of the NKT TCR led to differing patterns of CD1d–Ag
reactivity. For example, the CDR3b loop modulated the extent of
CD1d autoreactivity and, hence, the functional response to lipid
Ags, despite not contacting the Ag directly25,35. Moreover, the
heightened reactivity of the TRAV13-3þTRAJ50þ NKT cells
towards a-GlcCer was attributable to favourable interactions of
the a-GlcCer moiety with the TCR a-chain19. While some type II
NKT TCRs can dock differently on CD1d, these do not react with
a-GalCer and utilize entirely different TCR V genes36,37. Thus,
the question of whether CD1d–a-GalCer-reactive NKT abTCRs
can adopt alternative binding modes that may provide greater
diversity in Ag recognition remains to be determined, and this
represents an important issue in understanding the scope of lipid
Ag recognition by NKT cells.
Here we describe a diverse population of CD1d–a-GalCer
reactive cells that we termed ‘atypical NKT cells’ because they
lack the invariant TRAV10þTRAJ18þ a-chain and the
TRBV25-1 b-chain that are inherent to type I NKT cells.
These atypical NKT cells exhibited differing speciﬁcities
towards lipid Ags compared with that of type I NKT TCRs.
Importantly, these atypical NKT cells could respond to
glycolipid Ag presented by CD1d with diverse cytokine
production, similar to type I NKT cells. Crystal structures of
two of these atypical NKT TCRs in complex with CD1d–a-
GalCer showed that, in contrast to type I NKT cell TCRs
that dock over the F0-pocket of CD1d–a-GalCer, these
atypical TCRs docked orthogonally over the A0-pocket of
CD1d–a-GalCer. Furthermore, the interactions with the lipid
Ag were completely distinct from those observed with type I
NKT TCRs engaging a-GalCer-CD1d complexes. Thus,
variations in the CD1d–a-GalCer-reactive NKT TCR reper-
toire can manifest in alternative docking strategies on CD1d
and diverse reactivity towards CD1d-restricted lipids.
Results
A diverse human type I NKT cell repertoire. A deﬁning
characteristic of type I NKT cells is their reactivity towards the
prototypical type I NKT cell Ag, a-GalCer, presented by CD1d6.
The human type I NKT cell repertoire is comprised of the
invariant TRAV10þTRAJ18þTRBV25-1þ NKT cells. Given
that a range of TCR b-chains can support CD1d–a-GalCer
recognition in mice8, we were interested in exploring whether a
similar population of TRBV25-1 NKT cells existed in humans.
To establish this, we isolated and expanded CD1d–a-GalCer
reactive NKT cells from healthy human blood donors and
performed analytical ﬂow cytometry to identify non-canonical
NKT cell TCR subsets, by staining with antibodies speciﬁc for
TRAV10 and TRBV25-1, along with gdTCR and TRDV1 to
exclude CD1d–a-GalCer-reactive gd T-cells from the analysis22.
Using this approach, we detected a clear population of
TRBV25-1 NKT cells, that, in most donors, did not react
with ‘endogenous’ CD1d tetramers, thus implying these cells
recognized a-GalCer presented by CD1d (Fig. 1a). Consistent
with earlier studies17,38, a population of TRAV10 NKT
cells was also detected, although interestingly, the proportion
of the TRBV25-1 and the TRAV10 populations within
each sample did not always coincide, suggesting that these
two subsets were at least partially mutually exclusive. Co-
staining with CD4 and CD8a co-receptors revealed a variable
pattern of expression on the CD1d–a-GalCer-restricted
TRBV25-1 cells compared with type I NKT cells
(Fig. 1a,b). A more extensive phenotypic analysis of four
donors with a detectable population of these cells indicated
that while both TRBV25-1þ (type I) and TRBV25-1
CD1d–a-GalCer-reactive cells expressed NKG2D (three out
of four donors each), there was very little or no expression of
a panel of killer inhibitory receptors (including CD158A/B/F/
G/H) or CD56 (Supplementary Fig. 1). Furthermore, CD161
was clearly expressed on the TRBV25-1 cells in two out of
four donors, versus three out of four donors for type I NKT
cells. Thus, while there appears to be signiﬁcant heterogeneity
in the phenotypic proﬁles of TRBV25-1 cells between
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donors, at least in some cases they resemble type I NKT cells.
Analysis of additional donors conﬁrmed that the gdTCR
TRBV25-1 subset was clearly detectable in 11/19
individuals, where they ranged from 0 to 10% of all CD1d–
a-GalCer reactive (type I) NKT cells (Fig. 1c). Given that
type I NKT cells generally represent B0.01–0.1% of
peripheral blood lymphocytes, this indicates that these cells
are normally quite rare, and in most cases, we could only
readily detect them after in vitro enrichment/expansion of
CD1d–a-GalCer-reactive cells.
To determine the paired TCR a and b chain usage of these
cells, we performed single-cell TCR sequencing and compared
gene usage with TRAV10þTRBV25-1þ type I NKT cells sorted
from the same donors. The sequencing results conﬁrmed that
there appeared to be two distinct subsets of non-canonical CD1d–
a-GalCer-reactive T cells based on TCR gene usage. One of these
exhibited a TRAV10TRBV25-1þ phenotype, and was only
identiﬁed within the TRAV10 population, whereas the second
was TRAV10TRBV25-1 , and was present within both the
TRAV10 and TRBV25-1 populations (Table 1). Interestingly,
these data also revealed a close association between TRAJ18 and
TRBV25-1 gene usage. For example, eight out of eight unique
TRBV25-1þ TCR sequences that lacked the TRAV10 TCR
a-chain still expressed TRAJ18. In contrast, only one out
of fourteen unique TCR sequences that were TRBV25-1
utilized TRAJ18 (Po0.0001; Fisher’s exact test). Instead, this
TRBV25-1 population displayed a broad spectrum of
TRAV and TRAJ gene usage (Table 1). Thus, from
TRBV25-1 cells, 13 different TCR a-chains utilized TRAV
genes other than TRAV10 and these paired with a range of
TRAJ genes, including TRAJ8, 24, 27, 30, 44, 48 and 52.
These TRAJ segments displayed very limited sequence
identity with the TRAJ18 gene segment, and minimal inter-
sequence or inter-donor similarity (Table 1). The CDR1a and
CDR2a loops displayed notable sequence variability, and
moreover, on account of variable N-region additions and
deletions, the length of the CDR3a loop varied from 10 to 14
amino acids among the TRBV25-1 subset, compared with
the highly restricted CDR3a of both the TRAV10
TRBV25-1þ and TRAV10þTRBV25-1þ subsets, where 8/
8 and 11/11 clones, respectively, had an invariant CDR3a
length of 13 residues (Table 1). In addition, the TCR b-chain
gene usage was highly diverse, and included TRBV2, 4-1, 6-5,
7–8, 11-2, 12-5, 20-1 and 28, along with diverse CDR3b
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Figure 1 | Identiﬁcation of CD1d–a-GalCer reactive atypical NKT cells. (a) Flow cytometry of CD1d–a-GalCer reactive cells enriched and expanded from
PBMCs from three healthy human donors. TRDV1 gdTCR cells were analysed for the expression of TRBV25-1 versus CD1d-endogenous tetramer or
CD1d–a-GalCer tetramer (left-hand density plots). TRDV1 gdTCR CD1d–a-GalCer tetramerþ cells were analysed for the expression of TRAV10 (middle
density plots). CD1d–a-GalCer tetramerþ TRBV25-1þ type I cells and CD1d–a-GalCer tetramerþ TRBV25-1 cells were analysed for the expression of
CD4 and CD8a (right-side density plots). (b) The mean percentage of double negative (DN), CD4þ and CD8þ cells among CD1d–a-GalCer tetramerþ
TRBV25þ Type I cells (dark grey) and CD1d–a-GalCer tetramerþ TRBV25 cells (light grey). Each symbol represents cells from a different donor (n¼6).
(c) The mean percentage of CD1d–a-GalCer tetramerþ TRBV25 cells of total CD1d–a-GalCer reactive NKTcells, from 19 individual donors. Donors that
showed no clear population of atypical NKT cells were given an arbitrary value of 0.01%.
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sequence and length (Table 1), and no identical clones were
identiﬁed between separate donors. Accordingly, the CD1d–
a-GalCer-reactive T-cell compartment is not only comprised
of dominant TRAV10þTRAJ18þTRBV25-1þ and sub-
dominant TRAV10TRAJ18þ TRBV25-1þ ‘public’ reper-
toires, but in many cases, it also includes diverse TRAV10
TRAJ18TRBV25-1 ‘private’ TCR repertoires. We refer
to these latter cells as ‘atypical’ NKT cells.
Differing patterns of Ag reactivity. A feature of the type I NKT
TCR is that it not only reacts with a-GalCer, but also imbues
reactivity to a range of other self and foreign ligands. To establish
the Ag-reactivity proﬁle of atypical NKT cells, we stained
CD1d–a-GalCer tetramer-enriched and expanded PBMC
samples from healthy donors with a panel of CD1d–Ag tetramers,
and compared the TRBV25-1þ type I and TRBV25-1 atypical
NKT cells within each donor. While all type I NKT cells bound to
a-GalCer and a-GlcCer-loaded CD1d, many of the atypical NKT
cells failed to stain with a-GlcCer-loaded CD1d tetramers
(Fig. 2a). As we have previously published12, human type I NKT
cells exhibited a strong dependence on the 30-OH moiety of
a-GalCer as evidenced by their lack of reactivity to 30-deoxy
a-GalCer. However, subsets of atypical NKT cells in donors 1 and
4 clearly tolerated this substitution (Fig. 2a). Differences between
the Ag-reactivity proﬁle of type I and atypical NKT cells were also
evidenced using the OCH analogue of a-GalCer, which has a
truncated sphingosine chain. While this analogue is only poorly
recognized by type I NKT cells, some subsets of atypical NKT
cells, such as those in donor 1 and donor 3, still recognized this
Ag (Fig. 2a). Thus, the diverse TCR expression by atypical NKT
cells facilitates an altered and mixed pattern of CD1d–Ag
reactivity compared with type I NKT cells.
To conﬁrm the non-canonical TRBV25-1 atypical NKT cell
TCRs (Table 1) were indeed CD1d-restricted, we generated a
panel of Jurkat T-cell lines transduced with TRBV25-1 TCRs
and examined their ability to bind CD1d tetramers loaded with a
range of lipid Ags. We selected four TRBV25-1 TCRs that
represented a cross-section of the TCRa and TCRb chain usage:
clones 9C1 (TRAV21þTRAJ8þTRBV7–8þ ; Table 1, sequence #13);
9B1 (TRAV38-1þTRAJ48þTRBV9; Table 1, sequence #1); 9B2
(TRAV12-3þTRAJ27þTRBV6-5þ ; Table 1, sequence #2); 9B3
(TRAV13-2þTRAJ24þTRBV20-1þ ; Table 1, sequence #3) and
two controls, namely a Jurkat pHLA-speciﬁc irrelevant TCR
(TRAV17þTRBV16þ ) and an SKW3 TRAV10þTRAJ18þ
TRBV25-1þ type I NKT TCRþ cell line (SKW3.NKT15)
(Fig. 2b). As expected, the pHLA-speciﬁc TCR did not bind to
CD1d–Ag, while the SKW3.NKT15 cell line bound to CD1d–a-
GalCer, but not CD1d tetramer loaded with endogenous Ags
(Fig. 2b). The 9C1, 9B1, 9B2 and 9B3 Jurkat cell lines all bound to
the CD1d–a-GalCer tetramer, but not to CD1d-endo, thereby
conﬁrming the CD1d-restriction and a-GalCer reactivity of these
TCRs isolated from human PBMCs (Fig. 2b). While the
SKW3.NKT15 cell line could readily bind CD1d–a-GlcCer, the
atypical NKT TCRs did not tolerate this substitution, suggesting
clear differences in how the atypical NKT TCRs interacted with
the glycosyl headgroup compared with type I NKT TCRs
(Fig. 2b). Similar to the trends in Fig. 2a, these cell lines exhibited
a differential pattern of reactivity to the a-GalCer analogues
Table 1 | Non-canonical CD1d–a-GalCer-reactive TCR sequences.
Sequence Donor TCRa TCRb
TRAV-TRAJ CDR1a CDR2a CDR3a TRBV-TRBJ CDR1b CDR2b CDR3b
TRBV25-1
1 ‘9B1’ 1 TRAV38-1-TRAJ48 TSENNYY QEAYKQQN CAFILFGNEKLTF TRBV9-TRBJ2-3 SGDLS YYNGEE CASSVDRGRPDTQYF
2 ‘9B2’ 1 TRAV12-3-TRAJ27 NSAFQY TYSSGN CAMSGDLNTNAGKSTF TRBV6-5-TRBJ1-5 MNHEY SVGAGI CASSQGPFQPQHF
3 ‘9B3’ 1 TRAV13-2-TRAJ24 NSASDY IRSNMDK CAEKGMTTDSWGKLQF TRBV20-1-TRBJ1-6 DFQATT SNEGSKA CSAQTRGDSYNSPLHF
4 1 TRAV13-1-TRAJ52 DSASNY IRSNVGE CAASSGGTSYGKLTF TRBV4-1-TRBJ2-5 MGHRA YSYEKL CASSSQLLPGAPETQYF
5 1 (a) TRAV26-1-TRAJ42 TISGNEY GLKNN CIVRGSMMNYGGSQGNLIF TRBV4-1-TRBJ2-2 MGHRA YSYEKL CASSQDPSGVTGELFF
(b) TRAV5-TRAJ29 DSSSTY IFSNMDM CAESSNLSGNTPLVF
6 1 TRAV23/DV6-TRAJ30 NTAFDY IRPDVSE CAAELVRDDKIIF TRBV4-1-TRBJ2-1 MGHRA YSYEKL CASSQERERRILAGGPNEQFF
7 1 TRAV26-2-TRAJ44 TISGTDY GLTSN CILRDPLRGTASKLTF TRBV2-TRBJ1-4 SNHLY FYNNEI CASTSNTGTGGFANEKLFF
8 1 TRAV26-2-TRAJ48 TISGTDY GLTSN CILRDGFGNEKLTF TRBV4-1-TRBJ2-1 MGHRA YSYEKL CASSQVSSPGVPNEQFF
9 2 TRAV1-1-TRAJ21 TSGFYG NGLDGL CAVSRSLNFNKFYF TRBV28-TRBJ1-5 MDHEN SYDVKM CASSLPGQGRQPQHF
10 3 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV11-2-TRBJ2-7 SGHAT FQNNGV CASSPRDSYEQYF
11 3 TRAV12-3-TRAJ20 NSAFQY TYSSGN CAMIPFNDYKLSF TRBV12-5-TRBJ1-1 LGHNT FRNRAP CASGLVGTGEAFF
12 4 TRAV14/DV4-TRAJ43 TSDQSYG QGSYDEQN CAMREGPGDMRF TRBV20-1-TRBJ1-6 DFQATT SNEGSKA CSARDPTEDRKKGLNSPLHF
13 ‘9C1’ 5 TRAV21-TRAJ8 DSAIYN IQSSQRE CAGVNTGFQKLVF TRBV7-8-TRBJ2-7 SGHVS FQNEAQ CASSSRDLEQYF
14 7 (a) TRAV26-1-TRAJ43 TISGNEY GLKNN CIVSYNDMRF TRBV4-1-TRBJ2-2 MGHRA YSYEKL CASSHFGAGELFF
(b) TRAV41-TRAJ33 VGISA LSSGK CAASRPDSNYQLIW
TRAV10TRBV25-1þ
1 1 TRAV12-3-TRAJ18 NSAFQY TYSSGN CAMGDRGSTLGRLYF TRBV25-1-TRBJ2-1 MGHDK SYGVNS CASSEKTGLVHEQFF
2 3 TRAV12-3-TRAJ18 NSAFQY TYSSGN CAMSDRGSTLGRLYF TRBV25-1-TRBJ2-1 MGHDK SYGVNS CASSDLAGKGYNEQFF
3 5 TRAV27-TRAJ18 SVFSS VVTGGEV CAGYDRGSTLGRLYF TRBV25-1-TRBJ1-3 MGHDK SYGVNS CASSEYRAADSGNTIYF
4 5 TRAV12-2-TRAJ18 DRGSQS IYSNG CAVNDRGSTLGRLYF TRBV25-1-TRBJ2-5 MGHDK SYGVNS CASSSLAGVLLQETQYF
5 6 TRAV12-3-TRAJ18 NSAFQY TYSSGN CALCDRGSTLGRLYF TRBV25-1-TRBJ2-1 MGHDK SYGVNS CASSEFLQGGEPYNEQFF
6 6 TRAV12-3-TRAJ18 NSAFQY TYSSGN CAMSDRGSTLGRLYF TRBV25-1-TRBJ1-2 MGHDK SYGVNS CASSELDKFYGYTF
7 7 TRAV27-TRAJ18 SVFSS VVTGGEV CAGFDRGSTLGRLYF TRBV25-1-TRBJ1-3 MGHDK SYGVNS CASSFITDSGNTIYF
8 7 TRAV12-3-TRAJ18 NSAFQY TYSSGN CAMSDRGSTLGRLYF TRBV25-1-TRBJ2-2 MGHDK SYGVNS CASSEIGRGSYTGELFF
TRAV10þTRBV25-1þ (Type I)
1 2 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-7 MGHDK SYGVNS CASSDPRVHEQYF
2 2 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-1 MGHDK SYGVNS CASSDPAREQFF
3 2 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ1-2 MGHDK SYGVNS CASSEPTGTNYGYTF
4 3 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-2 MGHDK SYGVNS CASSEWAENTGELFF
5 3 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ1-1 MGHDK SYGVNS CASSEGAANTEAFF
6 3 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-1 MGHDK SYGVNS CASSERTGEPYNEQFF
7 3 (a) TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-2 MGHDK SYGVNS CASLGLTNTGELFF
(b) TRAV8-6-TRAJ10 SSVSVY YLSGSTLV CAVRFTGGGNKLTF
8 7 TRAV10-TRAJ18 VSPFSN MTFSEN CVVIDRGSTLGRLYF TRBV25-1-TRBJ1-2 MGHDK SYGVNS CASSEYSAGGNGYTF
9 7 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-5 MGHDK SYGVNS CASSDPRGRETQETQYF
10 7 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ1-1 MGHDK SYGVNS CASSDRVNEAFF
11 7 TRAV10-TRAJ18 VSPFSN MTFSEN CVVSDRGSTLGRLYF TRBV25-1-TRBJ2-7 MGHDK SYGVNS CASSDPDTLKYEQYF
CDR, complementarity determining region; TCR, T-cell receptor.
Gene usage and CDR sequences of productively rearranged TCRa and TCRb chains derived from single-cell-sorted CD1d–a-GalCer tetramerþ cells. Sequences are categorized into TRBV25-1 ,
TRAV10 TRBV25-1þ and TRAV10þ TRBV25-1þ (type I) subsets. Red residues indicate those encoded, either partly or wholly, from non-germline bases.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10570
4 NATURE COMMUNICATIONS | 7:10570 | DOI: 10.1038/ncomms10570 |www.nature.com/naturecommunications
30-deoxy-a-GalCer, 40-deoxy-a-GalCer and OCH (Supplementary
Fig. 2).
Type I NKT cells can recognize b-linked self-ligands by
moulding these ligands into a structural conformation resembling
their a-linked counterparts, albeit with reduced afﬁnity25.
Notably, in contrast to the type I SKW3.NKT15 cell line, we
detected clear reactivity of Jurkat.9B1 and Jurkat.9B2 cell lines to
b-GlcCer (Fig. 2b). This b-GlcCer reactivity, in the absence of
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a-GlcCer reactivity, is an indication that these atypical NKT
TCRs were not reacting with any potential a-GlcCer
contamination within the b-GlcCer preparation39. These 9B1
and 9B2 TCRs also reacted to a lesser extent with b-GalCer
(Fig. 2b), but none reacted with the type II NKT cell ligand
sulfatide or the ganglioside GD3 (Supplementary Fig. 2). In
addition, and in contrast to human type I NKT cells, there was
no cross-species reactivity of any of these atypical NKT TCRs
TCRs towards mouse CD1d–a-GalCer (Supplementary Fig. 2).
Therefore, non-canonical TRBV25-1 NKT cell TCRs are
capable of recognizing a diverse array of both a- and b-linked
lipid Ags, with a spectrum and hierarchy of reactivity that is
distinct from typical type I NKT cells.
To test the Ag responsiveness of atypical NKT cells, we isolated
CD1d–a-GalCer tetramerþ TRBV25-1 cells from PBMC by
ﬂow cytometric sorting, and then in vitro-expanded these cells
with anti-CD3/CD28 in the presence of irradiated allogeneic
PBMC for 2 weeks. Using this approach, seven out of eight
donors had a clear population of atypical NKT cells after
expansion, as well as the recently described CD1d–a-GalCer
tetramerþ TRDV1þ d/ab NKT cells40 (Supplementary Fig. 3),
with typical yields of B104–106 cells for each subset per donor,
after expansion. We re-sorted these populations, along with type I
NKT cells (CD1d–a-GalCer tetramerþ TRBV25-1þ ) and
control (CD1d–a-GalCer tetramer ) T cells derived from the
same cultures, and measured cytokine production after a 24 h
challenge with different lipid Ag in the presence of CD1d-
expressing APCs. Consistent with their tetramer reactivity,
atypical NKT cells from ﬁve out of seven donors elicited a clear
response following challenge with a-GalCer, producing both Th1-
(IFN-g, IL-2) and Th2- (IL-4, IL-13) type cytokines, compared
with control cultures containing APCs alone (Fig. 2c). Both type I
(seven out of seven donors) and d/ab (six out of seven donors)
NKT cells responded in a similar fashion, however as expected,
the control T cells did not respond to any lipid Ag (none of the
seven donors) despite responding to PMA/ionomycin. Consistent
with the tetramer-staining patterns, most atypical NKT cells
exhibited reduced reactivity to a-GlcCer compared with type I
NKT cells. Thus, these data conﬁrm that atypical NKT cells can
respond to glycolipid Ag presented by CD1d with diverse
cytokine production, similar to type I NKT cells.
Next, using CD69 upregulation as a marker of functional
activation, we examined the ability of the transduced Jurkat.NKT
cell lines to be activated in the presence of C1R cells expressing
CD1d plus deﬁned Ag. Following overnight co-culture with C1R
cells expressing intermediate or high levels of CD1d, but not
CD1d C1R WT cells, all the atypical Jurkat.NKT cell lines
showed clear signs of activation (Fig. 3a). This was despite no
obvious binding to the CD1d-endogenous tetramers (Fig. 2b),
suggesting the activation assays were more sensitive than the
tetramer-based assays. This also conﬁrmed that these atypical
NKT TCRs are capable of initiating cellular activation following
TCR ligation by CD1d–Ag. Addition of graded concentrations of
a-GalCer to these co-cultures resulted in greater activation of the
Jurkat.9C1, 9B1 and 9B3 cell lines, yet only appeared to
marginally enhance activation of the Jurkat.9B2 cell line
(Fig. 3b). Thus, these data show that non-canonical TRBV25-1
atypical NKT cell TCRs confer functional reactivity to CD1d, but
they also demonstrate diverse and distinct patterns of Ag
reactivity compared with TRAV10þTRAJ18þ type I NKT cells.
Afﬁnity towards CD1d–Ag. Using surface plasmon resonance
(SPR), we next determined the afﬁnity of two atypical NKT TCRs
from clones 9C1 and 9B2, towards CD1d bound to a-GalCer and
variants thereof. These two TCRs were selected based on their
contrasting Ag reactivity proﬁles, whereby the 9C1 TCR
demonstrated a strong dependence on a-GalCer for activation,
whereas the 9B2 TCR, whilst still reactive to CD1d–a-GalCer
tetramers, demonstrated an auto-reactive proﬁle that was
associated with less Ag-speciﬁc activation. We expressed, refolded
and puriﬁed the soluble ectodomains of both TCRs to high yields,
and passed them over CD1d–Ag coupled to a sensor chip.
The 9C1 and 9B2 TCRs did not bind, or bound very poorly, to
CD1d-endogenous tetramers respectively, consistent with the
tetramer-binding data (Fig. 4). The 9C1 TCR and 9B2 TCR both
bound to CD1d–a-GalCer with an afﬁnity (KD) of 3.9 mM and
4.0 mM respectively, values that, while comparable to many
TCR–pMHC interactions, were weaker than the afﬁnity of the
canonical type I NKT TCR (NKT15) towards CD1d–a-GalCer
(KD¼ 0.19 mM) (Fig. 4). The afﬁnity of the 9C1 and 9B2 TCRs
towards CD1d-30-deoxy-a-GalCer (KD¼ 1.4 mM and 3.6 mM,
respectively) was comparable or moderately higher than that of
CD1d–a-GalCer (Fig. 4). This is in stark contrast to the NKT15
TCR, which bound with much lower afﬁnity to CD1d-30-deoxy-
a-GalCer (KD¼ 4.7 mM, B20-fold reduction) (Fig. 4)12,26.
Conversely, the 9C1 TCR exhibited a markedly reduced afﬁnity
(KD4100mM) towards the 40-deoxy-a-GalCer analogue, while
there was no negative impact of this analogue on NKT15 or 9B2
TCR binding (Fig. 4). Consistent with tetramer staining and
functional studies, a-GlcCer was bound with much lower
afﬁnity by 9C1 TCR and 9B2 TCR (KD4100 mM and 19 mM,
respectively), yet was well-tolerated by NKT15 TCR
(KD¼ 0.12 mM) (Fig. 4). The recognition of 40-deoxy-a-GalCer
but not a-GlcCer by 9B2 TCR implies that the equatorial 40-OH
group of a-GlcCer may cause a conformational change in CD1d
and/or the lipid headgroup, which is not tolerated by 9B2. Thus,
while the atypical NKT TCRs and type I NKT TCRs are reactive
towards a-GalCer, they clearly differ in their ﬁne speciﬁcity
towards CD1d-restricted Ags.
Overview of atypical NKT TCR ternary complexes. Next, to
establish how atypical NKT TCR usage manifested in CD1d–Ag
recognition, we determined the crystal structures of
the 9C1 TCR-CD1d–a-GalCer and 9B2 TCR-CD1d–a-GalCer
ternary complexes to 2.5 and 3.1 Å resolution, respectively
(Supplementary Tables 1–3, Supplementary Fig. 4). The 9C1
Figure 2 | Lipid reactivity of atypical TRBV25-1 NKTcell lines. (a) CD1d tetramer staining of CD1d–a-GalCer-reactive cells enriched and expanded from
PBMCs from four healthy human donors. Plots show TRBV25-1 versus CD1d tetramers loaded with a-GalCer (C24:1), ‘endogenous’ antigen, a-GlcCer, 30-
deoxy-a-GalCer, 40-deoxy-a-GalCer or OCH. Data show one of two representative experiments. (b) Histograms depicting human CD1d–lipid antigen
tetramer staining (white histograms) of CD3þ Jurkat T-cell lines transduced with the 9C1, 9B1, 9B2, 9B3 atypical NKT cell TCRs or with the NKT15 type I
NKT cell TCR or an irrelevant pHLA-speciﬁc TCR control, overlaid with ‘endogenous’ tetramers (grey histograms). Numbers in each histogram represent
CD1d–lipid tetramer mean ﬂuorescence intensity. Data are representative of two separate experiments. (c) Graphs depict the mean IFN-g, IL-2, IL-4 and
IL-13 concentrations in culture supernatants of 4–5 103 in vitro-expanded/puriﬁed CD1d–a-GalCer tetramerþ TRBV25-1þ (type I NKT, white bars),
CD1d–a-GalCer tetramerþ TRBV25-1 (atypical NKT, black bars), CD1d–a-GalCer tetramerþ TRDV1þ gdTCR (d/ab NKT, grey bars), and
CD1d–a-GalCer tetramer (control T cells, hashed bars), with different lipid Ag (0.5mgml 1) in the presence of K562.CD1d APCs or PMA/ionomycin
for 24 h. Data are representative of n¼ 5–7 donors, with each symbol depicting a separate donor (each symbol derived from n¼ 1–2 technical replicates).
Data are pooled from two independent experiments.
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(Fig. 5a) and 9B2 (Fig. 5b) TCRs adopted two distinct docking
modes atop CD1d–a-GalCer, both of which markedly contrasted
the salient parallel docking mode over the F0-pocket that is
observed for NKT15 TCR-CD1d–a-GalCer (Fig. 5c) and all other
type I NKT TCR–CD1d–Ag complexes determined to date8. The
9C1 TCR docked orthogonally (75) across the A0-pocket of
CD1d, in which the 9C1 TCR a-chain was located above the
CD1d a2-helix, while the TCR b-chain was more centrally
positioned over the CD1d a1-helix (Fig. 5a). On ligation, the
buried surface area (BSA) of the 9C1 TCR was B750Å2,
whereupon the TCR a-chain contributed the most (B460Å2) to
the 9C1 TCR-CD1d–a-GalCer interface (Fig. 5a). We also
determined the structure of the 9C1 TCR in the non-liganded
state (Supplementary Table 1), thereby allowing us to compare
the mode, and plasticity of atypical NKT TCR recognition to that
of typical type I TCR recognition of CD1d–a-GalCer (Figs 5
and 6). The 9C1 TCR did not undergo a major structural
rearrangement on CD1d–a-GalCer engagement, although the
CDR3 loops moved to bind the a-GalCer moiety (Supplementary
Fig. 4d). The 9B2 TCR also sat over the A0-pocket of CD1d with a
docking angle of B110 across the Ag-binding cleft (Fig. 5b).
Thus, while the overall position of the 9B2 TCR a-chain was
similar to the 9C1 TCR a-chain atop CD1d (centre of mass
(COM) difference of 0.5 Å) (Supplementary Fig. 4c), the 9B2 TCR
b-chain was located more towards the extreme end of the CD1d
A0-pocket, with a COM difference of 13Å and rotational
difference of 35 compared with the 9C1 TCR b-chain (Fig. 5b
and Supplementary Fig. 4c). In comparison, the BSA at the 9B2
TCR-CD1d–a-GalCer interface was 720Å2 (Fig. 5b). The docking
mode of these atypical NKT TCRs were more analogous to the
mouse type II NKT cell XV19 TCR–CD1d–sulfatide ternary
complex (Fig. 5d), although consistent with the deﬁnition of type
II TCRs, XV19 fails to interact with CD1d–a-GalCer36,37.
Accordingly, this represents the ﬁrst description of how
variations in NKT TCR usage can manifest in a markedly
different binding mode towards CD1d–a-GalCer.
Atypical NKT TCR interactions with CD1d. In the 9C1
TCR–CD1d–a-GalCer ternary complex, the CDR3a loop (35%
BSA) played a principal role in the interactions (Fig. 5a). Notably,
the characteristics and conformation of the TRAJ8-encoded
CDR3a loop of the 9C1 TCR contrasted that of the polar-rich
TRAJ18-encoded CDR3a loop of the NKT15 TCR (Table 1). The
CDR1a and CDR2a loops of the 9C1 TCR exclusively contacted
the CD1d a2-helix, with Ser52a hydrogen bonding to Glu156, the
aliphatic moiety of which contacted Tyr31a (Fig. 6a left panel,
Supplementary Table 2). Trp153 of CD1d also packed against
Tyr31a, and nestled against the CDR3a loop, forming van der
Waals (vdw) contacts with its main chain as well as Gln112a
(Fig. 6a, left panel). Here, the CDR3a loop contacted residues
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from the a2-helix (spanning from Trp153–Trp160), and the
a1-helix (spanning Thr65–Val72). As such, the CDR3a was
wedged within the Ag-binding cleft, with Thr109a stacking
against Trp160 and hydrogen bonding to Thr157 of CD1d, while
Gln112a formed vdw contacts with Val72 (Supplementary
Table 2) and hydrogen bonded to His68 of CD1d (Fig. 6a, left
panel). The interactions between the 9C1 TRBV7–8-encoded
TCR b-chain and CD1d were more limited, being largely domi-
nated by the CDR2b (BSA 14%) and neighbouring framework
regions ligating to the a1-helix of CD1d. Here Gln57b and
Asn58b hydrogen bonded to Ser76 and Arg79 of CD1d, respec-
tively, while Leu66b packed against Val72 (Fig. 6a, middle panel).
In the 9B2 TCR ternary complex, the TCR a-chain chain
mediated most of the interactions with CD1d–a-GalCer (BSA
64%), within which the CDR3a loop, the characteristics of which
are also distinct from the TRAJ18-encoded CDR3a loop, was the
principal contributor to the interface (32% BSA) (Figs 5b,6b left
panel). The CDR1a (BSA 15%) and CDR2a (BSA 12%) made
exclusive contacts with the a2-helix of CD1d, whereupon Tyr32a
wedged between Trp153 and Trp160 and hydrogen bonded to
Thr157 and Trp160; Trp160 also packed against Gln31a (Fig. 6b
left panel). Trp153 of CD1d also stacked against Tyr57a, which
occupied the same location as Tyr31a from the CDR1a loop of
the 9C1 TCR (Fig. 7). The CDR2a loop interactions were
enhanced by the neighbouring framework residue, Lys82a, salt-
bridging to Glu156 of CD1d (Supplementary Table 3). Central to
the CDR3a loop-mediated contacts was Leu110a, which sat
within the central axis of the Ag-binding cleft and formed vdw
contacts with Asn62, Leu66, Trp160 and Thr165 (Fig. 6b, left
panel and Supplementary Table 3). Supplementing these inter-
actions was Ala114a, which was packed against the a1-helix and
the main chain carbonyls of Leu110a, and Ala114a forming
hydrogen bonds with Asn62 and Thr65 of CD1d, while Asn111a
hydrogen bonded to Gln168 (Fig. 6b). Regarding the 9B2 TCR
b-chain interactions, the CDR3b loop was the principal
contributor to this interface (BSA 20%), as the CDR1b and
CDR2b loops played lesser roles (7 and 5% BSA respectively).
Here Tyr31b, Val57b and Ile61b aligned to form a focused
interaction site spanning residues 64–68 on the a1-helix of CD1d
(Supplementary Table 3). The CDR3b loop was positioned
between the a1- and a2-helices, where Phe111b plugged a
hydrophobic-lined cavity formed by Thr65, His68, Ile69 and
Trp160 (Fig. 6b, middle panel). Notably, Phe111b and Gln112b
of the 9B2 TCR mirrored the position of Phe111a and Gln112a,
respectively, from the 9C1 TCR (Figs 6b and 7). In both 9C1 TCR
and 9B2 TCR ternary complexes, the three CDRa loops and the
CDR3b are involved in mediating the CD1d interactions. This is
in clear contrast to the classical NKT15 type I ternary complex,
whereby only the CDR3a contacted the CD1d molecule while
the CDR3b was not involved in any interactions with CD1d
(Fig. 6c, left and middle panels). Interestingly, while there were
notable differences in the sequences of the 9C1 and 9B2 TCRs
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Figure 4 | Afﬁnity of non-canonical TRBV25-1 NKT cell TCRs to CD1d–Ag. The afﬁnity of TCR-CD1d–Ag interactions were determined by surface
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10570
8 NATURE COMMUNICATIONS | 7:10570 | DOI: 10.1038/ncomms10570 |www.nature.com/naturecommunications
and respective interatomic TCR-CD1d contacts, there was
nevertheless a degree of focused structural mimicry within
these atypical type I NKT TCR–CD1d–a-GalCer ternary
complexes (Fig. 7). Thus, atypical and type I NKT TCRs engaged
CD1d–a-GalCer in a markedly different manner.
Interactions with a-GalCer. In both the 9C1 and 9B2 TCR
ternary complexes, the electron density for a-GalCer was
unambiguous (Supplementary Fig. 4a,b). While the positioning of
a-GalCer was very similar within the ternary complexes of the
atypical NKT TCR and the type I NKT TCR complexes, the
ensuing interactions with the lipid Ag were markedly different. In
the 9C1 TCR ternary complex, both the a- and b-chains mediated
lipid Ag recognition, with direct interactions arising from the
CDR3a, CDR2b and CDR3b loops. To enable this, the CDR3b
residues (Ser108b, Arg109b, Asp110b and Leu111b) and
Gln112a in the CDR3a rearranged to accommodate the Ag
(Supplementary Fig. 4d). Here, the main chain carbonyl of
Arg109b hydrogen bonded to the 40-OH of a-GalCer, the latter of
which also contacted Ser31b via a water-mediated hydrogen bond
(Fig. 6a, right panel). Further, a water-mediated hydrogen
bond between the 30-OH and Tyr31a was observed. The 60-OH
hydrogen bonded to Gln112a and Gln57b (Fig. 6a) and
interacted with the framework residue Tyr55b (Supplementary
Table 2). While, in the 9B2 TCR ternary complex, the inter-
actions with the a-GalCer moiety were extremely limited, namely,
Gln112b solely contacted the 60-OH of a-GalCer (Fig. 6b, right
panel). Both these atypical NKT TCR–a-GalCer contacts con-
trasted with that of the type I NKT TCR ternary complex. Here
interactions with a-GalCer were mediated only via the type I
NKT TCR a-chain, where the 20-OH, 30-OH and 40-OH groups
are closely sequestered by the CDR1a and CDR3a loops, while
the 60-OH moiety was solvent exposed (Fig. 6c, right panel).
Given the fundamental differences in the contacts with Ag, we
probed the importance of the 9C1 and 9B2 TCR residues that
contacted the a-GalCer moiety. To establish this, we undertook a
mutagenesis/SPR approach on the 9C1 and 9B2 TCRs. For the
9C1 TCR, this included analysing the impact of nine mutants:
Tyr31aAla, Tyr31aPhe, Gln112aAla, Ser31bAla, Tyr55bAla,
Tyr55bPhe, Gln57bAla, Arg109bAla and Leu111bAla, while for
the 9B2 TCR, this involved Gln112bAla mutant only (Table 2).
For the 9C1 TCR, while the Ser31bAla mutant had no effect,
mutations of the residues contacting the 60-OH of a-GalCer,
a b c d
Figure 5 | Overview of the docking of atypical NKT TCR ternary complexes. Ternary complexes of (a) human 9C1 TCR–CD1d–a-GalCer, (b) 9B2
TCR–CD1d–a-GalCer, (c) NKT15 TCR–CD1d–a-GalCer (PDB code 2PO6 (ref. 27) and (d) mouse XV19 TCR–CD1d–sulfatide (PDB code 4EI5 (ref. 36).
Top panels depict an overview of each structure, middle panels illustrate the TCRs docking onto CD1d and lower panels show the TCR footprints on the
CD1d–Ag molecular surface. The CD1d and b2-microglobulin molecules are coloured in light blue and light brown, respectively. 9C1 TCRa, brown; 9C1
TCRb, light pink; 9B2 TCRa, light green; 9B2 TCRb, purple; NKT15 TCRa, green; NKT15 TCRb, cyan; XV19 TCRa, yellow; XV19 TCRb, grey. The CDR loops
are coloured as follows: CDR1a, aqua; CDR2a, purple; CDR3a, red; CDR1b, green; CDR2b, orange; CDR3b, blue. The a-GalCer and sulfatide are coloured in
black and light brown sticks (top panel), or black and light brown spheres (middle and lower panels), respectively. In the middle panels, the centre of mass
of the respective TRAV and TRBV variable domains are shown as black spheres. In the bottom panels, the molecular surface of CD1d is coloured in
light grey.
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Figure 6 | Interactions at the CD1d–Ag–TCR interface. (a) Left panel, 9C1 TCR a-chain interactions with CD1d; middle panel, 9C1 TCR b-chain interactions
with CD1d; right panel, 9C1 TCR interactions with a-GalCer; (b) Left panel, 9B2 TCR a-chain interactions; middle panel, 9B2 TCR b-chain interactions with
CD1d; right panel, 9B2 TCR interactions with a-GalCer; (c) Left panel, NKT15 TCR a-chain interactions with CD1d; middle panel, NKT15 TCR b-chain
interactions with CD1d; right panel, NKT15 TCR interactions with a-GalCer. For clarity, only the hydrogen bonds are shown as black dashed lines and the
a1- and a2-helices of CD1d are shown as cartoon representation and coloured in light blue. CDR loops are coloured according to Fig. 5; spheres represent
water molecules.
Figure 7 | Molecular mimicry between the 9B2 and 9C1
TCR-CD1d–a-GalCer complexes. Superposition of the 9B2 and 9C1 TCR
ternary complexes, coloured in grey and light blue, respectively. The
superposition is based on the CD1d molecules of each complex.
For clarity, only the CDR1a/CDR3b of 9C1 and the CDR2a/CDR3a 9B2
are shown.
Table 2 | Afﬁnity measurements of 9C1 and 9B2 TCR
mutants to CD1d–a-GalCer.
TCR KD (lM)
9C1 WT 4
9C1 Tyr31a-Ala 4200
9C1 Tyr31a-Phe 1.9
9C1 Gln112a-Ala 200
9C1 Ser31b-Ala 4.4
9C1 Tyr55b-Ala 180
9C1 Tyr55b-Phe 12
9C1 Gln57b-Ala 17
9C1 Arg109b-Ala 12
9C1 Leu111b-Ala 4200
9B2 WT 4.3
9B2 Gln112b-Ala 7.9
TCR, T-cell receptor.
Binding of soluble 9C1 and 9B2 mutants to CD1d–a-GalCer, as determined by surface plasmon
resonance. Dissociation constant (KD) values for 9C1 WT, Tyr31a-Ala, Gln112a-Ala, Ser31b-Ala,
Arg109b-Ala, Leu111b-Ala and 9B2 WT represent the mean of two independent experiments,
and 9C1 Tyr31a-Phe, Tyr55b-Ala, Tyr55b-Phe, Gln57b-Ala and 9B2 Gln112b-Ala are derived from
a single experiment.
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namely, Tyr55bAla, Tyr55bPhe, Gln112aAla and Gln57bAla
impacted on the binding afﬁnity relative to the wild-type 9C1
TCR. Although Leu111b interacted with the C6 and 40-OH of the
Ag via vdw contacts, the Leu111bAla mutation completely
ablated CD1d–a-GalCer recognition. The effect of this mutant
may be attributable to the major role Leu111b plays in contacting
CD1d. Interestingly, while the Tyr31aAla mutant abrogated
recognition, the Tyr31aPhe 9C1 variant increased the afﬁnity for
CD1d–a-GalCer, presumably by reinforcing the hydrophobic
character of the 9C1 TCR-CD1d–a-GalCer interface. For the 9B2
TCR, the Gln112bAla mutant resulted in a moderate reduction in
afﬁnity, but did not completely ablate binding. This suggests
that mutating Gln112b to Ala might enable a compensatory
interaction to form via another adjacent residue in the TCRb
chain (for example, Gln108b); or alternatively, that the
Gln112bAla mutant of 9B2 is more permissive for binding of
endogenous lipid Ags than the WT 9B2 protein, thus resulting in
a higher level of autoreactivity. Therefore, contrasting modes of
a-GalCer-centric interactions exist between the atypical NKT
TCRs and type I NKT TCRs.
Discussion
Human type I NKT cells are characterized by their expression of
the semi-invariant (TRAV10þTRAJ18þTRBV25-1þ ) TCR and
their strong reactivity to a-GalCer presented by CD1d6. The type
I NKT TCR resembles a pattern recognition receptor in that a
universal docking mode underpins type I NKT TCR–CD1d–Ag
recognition8,41. Our ﬁndings reveal that CD1d–a-GalCer reactive
NKT cells neither have to utilize the semi-invariant TCR, nor do
they necessarily have to recognize the resultant CD1d–Ag
complex in the consensus type I NKT TCR-CD1d docking
topology.
In humans, the type I NKT TCR recognizes a range of
chemically diverse lipid Ags by docking over the F0-pocket of
CD1d in a parallel manner42. Here the invariant TCR a-chain
contacts CD1d and the Ag, whereas the TCR b-chain contacts
CD1d only. Central to this interaction is the TRAJ18-encoded
CDR3a loop, a highly polar loop that makes a number of
complementary electrostatic interactions with CD1d–a-GalCer42.
The importance of the TRAJ18 gene segment for type I NKT cell
development is emphasized by the observations that TRAJ18-
deﬁcient mice have markedly impaired NKT cell numbers43.
However, there are exceptions to the use of the invariant TCR
a-chain by CD1d–a-GalCer-reactive NKT cells. For example,
populations of mouse TRAV13-3þTRAJ50þ and human
TRAV10TRAJ18þ NKT cells have been described
previously17,22,38. Furthermore, TCR sequencing of human
TRAV10 NKT cells showed that while most still expressed
TRAJ18, some other TRAJ genes were used in addition to a
number of other TCR TRBV genes21, although the speciﬁcity
of these TCRs was not veriﬁed. Thus, while variations in the
CD1d–a-GalCer-reactive NKT cell repertoire can impact the
functional responses and ﬁne speciﬁcity towards some Ags,
structural analysis of these interactions have nevertheless
suggested that they do so under the conﬁnes of the consensus
footprint on CD1d8.
As we had previously described a population of CD1d–a-
GalCer-reactive TRAV11TRAJ18 NKT cells in mice19, we
asked whether such a population of cells could exist in humans.
Using a-GalCer, we demonstrated a subset of NKT cells with
diverse TCR a and b chain usage. While diverse NKT TCR usage
is generally a feature of type II NKT cells, the NKT cells identiﬁed
here were reactive to the prototypic type I NKT cell Ag, a-GalCer.
This meant that these cells could neither be described as type I,
nor type II NKT cells, and hence we presently termed that as
atypical NKT cells. Notably, they were distinct from the
previously described mouse ‘Va10’ (TRAV13-3þ ) NKT
subset in that they utilized a diverse array of non-canonical
TCRa and TCRb chain gene segments, therefore suggesting
that no apparent mouse homologue of atypical NKT cells has
been described. The TRBV25-1 atypical NKT cells were
distinct from type I and other, previously deﬁned TRAV10
(but TRBV25-1þ ) non-canonical NKT cells, in that they also
did not utilize the TRAJ18 TCR gene segment. Thus, it
appears that TRAJ18 and TRBV25-1 are strongly associated
with, and may dictate, the archetypal type I NKT cell TCR
parallel docking footprint, since in their absence the atypical
NKT cell TCRs were able to adopt alternate docking
strategies. The basis for the strong association between
TRAJ18 and TRBV25-1 expression is unclear, although
these TCR elements dominate the interactions with CD1d–a-
GalCer in type I NKT TCR complexes. This may indicate
that, when used in concert, these TCR motifs preferentially
support NKT cell selection criteria during T-cell
development, or alternatively, facilitate preferential
recognition of a stimulatory sub-class of endogenous Ag.
These ﬁndings also highlight the fact that diverse TCR usage
can also be a feature of CD1d–a-GalCer-reactive NKT cells.
Notably, similar to type I NKT cells, these atypical NKT cells
could respond to glycolipid Ag presented by CD1d with
diverse cytokine production.
Importantly, this repertoire diversity also manifests in differing
afﬁnities and functional outcomes towards self- and foreign lipid
Ags, in that these atypical NKT TCRs appeared to be of lower
afﬁnity to the type I NKT TCRs and also exhibited differing ﬁne
speciﬁcities. Surprisingly, such differences were attributable to the
atypical NKT TCRs adopting a footprint on CD1d that was
markedly different to that of consensus F0-pocket docking mode
that has consistently been observed for all type I NKT TCRs to
date. Namely, two representative atypical NKT TCRs, 9C1 and
9B2, both adopted distinct docking modes above the A0-pocket of
CD1d, by binding in an orthogonal manner. These docking
modes were reminiscent of the mouse type II NKT TCR (clone
XV19) binding to CD1d presenting sulfatide, and moreover, the
distribution of contacts across the CDR loops of these atypical
NKT TCRs were more analogous to that of type II XV19 NKT
TCR recognition36,37. This A0-pocket docking mode also
resonated with the recently described gd TCR–CD1d–Ag
complexes, although naturally the details of the interatomic
contacts differed substantially22,44. In ﬁnding different solutions
to interact with CD1d, it was interesting to note that molecular
mimicry ‘hot spots’ underpinned 9C1 and 9B2 TCR
recognition. Namely, ‘aromatic motifs’ within different
regions of the TCRs were seen to play analogous roles in
contacting CD1d, despite arising from different regions of the
respective TCRs. Furthermore, the atypical NKT cell TCRs
also adopted differing strategies to interact with a-GalCer,
with interactions via the 60-OH of a-GalCer featuring
prominently in atypical NKT TCR recognition, in stark
contrast to typical type I NKT TCR recognition where this
motif is not involved in recognition8.
Our studies show that the human ab TCR, d/ab TCR and gd
TCR repertoire is sufﬁciently ﬂexible to recognize the same
Ag-presenting molecule displaying the same Ag via a number of
different mechanisms. Our ﬁndings imply that the TCR
repertoire provides signiﬁcant molecular scope for recognition
of diverse lipid-based Ags in the context of CD1d. Given that
a-GalCer is being explored as a potential immunotherapeutic
agent, and numerous analogues of a-GalCer have been generated
to improve the therapeutic efﬁcacy of this drug8,45,46, it is
important that we understand the impact of such modiﬁcations
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on the entire CD1d–a-GalCer-reactive NKT TCR repertoire. Our
ﬁndings have radically reshaped our understanding of NKT TCR
recognition.
Methods
Accession numbers. The structures of 9B2 TCR–CD1d–a-GalCer, 9C1
TCR–CD1d–a-GalCer and 9C1 TCR were deposited in the RCSB Protein Data
Bank (PDB) under the accession codes 4WWK, 4WW2 and 4WW1, respectively.
Flow cytometry. Blood samples from healthy blood donors were obtained from
the Australian Red Cross Blood Service under agreement number 13-04VIC-07,
and experiments were conducted in accordance with the University of Melbourne
Human Research and Ethics committee guidelines (approval number 1035100).
PBMCs were isolated by density gradient centrifugation (Histopaque-1077, Sigma).
Cells were stained with CD3e (UCHT1, eBioscience and Becton Dickinson), CD4
(RPA-T4, Becton Dickinson), CD8a (SK1, Becton Dickinson), CD19 (HIB19,
BioLegend), CD56 (HCD56, Biolegend), CD69 (FN50, Becton Dickinson),
CD158A/B/F/G/H (mixture of DX27, Biolegend, HP-MA4, eBioscience, and
UP-R1, eBioscience), CD161 (191B8, Miltenyi Biotec, or HP-3G10, Biolegend),
NKG2D (CD314, 1D11, Biolegend), TRAV10 (C15, Beckman Coulter), TRBV25-1
(C21, Beckman Coulter), TRDV1 (A13; a gift from L. Morretta, Istituto Giannina
Gaslini, Italy), isotype controls (mouse IgG2b, MPC-11, Biolegend and mouse
IgG1, MOPC-21, Biolegend) and 7-aminoactinomycin D viability dye (Sigma).
All antibodies were used at empirically determined dilution factors. Cells were
stained with human and mouse CD1d tetramers as previously described22.
CD1d–a-GalCer tetramerþ cells were enriched using anti-phycoerythrin magnetic
beads (Miltenyi Biotec), followed by cell sorting of CD3þ CD1d–a-GalCer
tetramerþ cells using a FACSAria (BD Biosciences). Cells were then expanded for
14–21 days using anti-CD3, anti-CD28, IL-2, IL-7 and phytohemagglutinin as
previously described22, and were analysed on an LSRFortessa (BD Biosciences).
Data analysis was performed using FlowJo (Tree Star Inc).
Lipids. C24:1 (PBS44) was kindly provided by P. Savage (Brigham Young
University). a-GalCer C26:0 was supplied by Alexis Biochemicals, and sulfatide
(C24:1), b-GalCer (C12) and b-GlcCer (C24:1) were purchased from Avanti Polar
Lipids. Disialo-ganglioside GD3 was purchased from Matreya. a-GlcCer (C20:2),
a-GalCer (C20:2 analogue), and OCH were produced in house (at the University of
Birmingham, UK). a-GalCer (C26:0 30 ,400-dideoxy- ‘30-deoxy-a-GalCer’ and C26:0
40,400-dideoxy ‘40-deoxy-a-GalCer’ analogues) were produced in house (at the
University of Connecticut)47. Lipids were dissolved in 0.5% v/v Tyloxapol
(Sigma), or buffer containing 0.5% v/v tween-20, 57mgml 1 sucrose and
7.5mgml 1 histidine, and loaded into CD1d at a three to sixfold molar excess
overnight.
TCR identiﬁcation. CD3þ CD1d–a-GalCer tetramerþ gdTCR TRBV25-1
cells, or alternatively CD3þ CD1d–a-GalCer tetramerþ TRAV10 cells, were
single-cell sorted from CD1d–a-GalCer tetramer-enriched/expanded NKT cells
(see above), and complementary DNA generated using SuperScript VILO
(Invitrogen) in accordance with manufacturer’s instructions. Transcripts
encoding TCRa and TCRb chains were ampliﬁed as described48, with the
exception of 9C1 TCRa, which was identiﬁed by 50-RACE PCR according to
manufacturer’s instructions (Invitrogen). Here complementary DNA was
generated from bulk-sorted CD1d–a-GalCer tetramerþ TRBV25-1 cells
with a gene-speciﬁc TRAC primer (50-GACCAGCTTGACATCACA-30),
followed by ampliﬁcation with a nested TRAC reverse primer (50-
GGGAAGAAGGTGTCTTCTGGAAT-30), and subsequent cloning of PCR
products into pGEM-T Easy (Promega). PCR fragments were separated using
a 1.5% agarose gel and DNA sequenced by Molecular Diagnostics (the
University of Melbourne). TCR sequence analysis was performed using the
IMGT online analysis interface, and TCR nomenclature, numbering and
CDR3 lengths are presented in accordance with the IMGT system49.
Unproductively rearranged TCR genes were excluded from analysis.
Generation of cell lines and stimulation assay. TCR constructs containing
full-length TCRa and TCRb chains separated by a 2A-cleavable linker were
synthesized (Genscript), and cloned into the pMIG2 plasmid. Generation of cell
lines was achieved by retroviral transduction of abTCR-deﬁcient Jurkat-76 cells
with both TCR and a 2A-cleavable human CD3edgz construct, using HEK293T
cells as packaging cells, essentially as previously described50. For stimulation assays,
3 104 TCR-expressing Jurkat-76 or SKW3 cells were co-cultured overnight, with
or without 3 104 C1R (either C1R WT, C1R.CD1dint or C1R.CD1dhi) cells, with
graded concentrations of lipid in round-bottom 96-well plates, and CD19 cells
were analysed by ﬂow cytometry for CD69 expression. For stimulation assays using
primary NKT cells, PBMCs were enriched for CD1d–a-GalCer-tetramerþ cells
using magnetic beads as described above, then CD3þ gdTCR CD1d–a-GalCer
tetramerþ TRBV25-1þ / cells were enriched by ﬂow cytometric sorting and
cultured for 2 days in the presence of plate-bound anti-CD3 (UCHT1,
10mgml 1), soluble anti-CD28 (CD28.2, 1 mgml 1), IL-2 (100Uml 1), IL-7
(50 ngml 1), PHA (0.5mgml 1), 105 irradiated allogeneic PBMC and 2 104
irradiated CD1d-expressing K562 cells, and subsequently maintained in media
containing IL-2 and IL-7. After B2 weeks, cultured cells were then re-sorted into
type I NKT (CD1d–a-GalCer tetramerþ TRBV25-1þ TRDV1 ), atypical NKT
(CD1d–a-GalCer tetramerþ TRBV25-1 TRDV1 ), d/ab NKT (CD1d–a-GalCer
tetramerþ gdTCR TRDV1þ ) and control T (CD1d–a-GalCer tetramer
TRBV25-1 TRDV1 ) cell subsets, and purity was conﬁrmed (495%). About
4–5 103 cells were cultured with 2 104 CD1d-expressing K562 cells, þ / lipid
Ag (each at 0.5 mgml 1), for 24 h in 50ml media containing no IL-2 or IL-7, and
cytokine concentrations were assayed by cytometric bead array(BD Biosciences)
according to manufacturer’s instructions.
Surface plasmon resonance. SPR experiments were conducted at 25 C on a
ProteOn XPR36 (Bio-Rad) instrument using HBS-T buffer (10mM HEPES, pH
7.4, 150mM NaCl and 0.005% surfactant P-20). Biotinylated human CD1d
was loaded with a-GalCer (C26:0), a-GlcCer (C26:0), 30-deoxy-a-GalCer and
40-deoxy-a-GalCer, and 400–600 RU was coupled to a GLC sensor chip surface
via streptavidin, after which free streptavidin was blocked with an injection of
D-biotin. Serial dilutions of puriﬁed soluble 9C1 TCR, 9B2 TCR, NKT15 TCR or
mutants thereof (starting TCR concentrations between 19.1 and 128 mM) were
injected at 25ml per minute for 60 s, simultaneously over test and control
(streptavidin alone) ﬂow cells, using HBS-T buffer. Data were referenced against
the control ﬂow cell and analysed using ProteOn Manager version 2.1 (Bio-Rad)
software, and KD, Ka and t1/2 values derived using a 1:1 Langmuir binding model.
For TCR mutant analysis, KD values were normalized against WT TCR KD values.
Generation of soluble TCRs and CD1d. The individual TCRa and b chains of the
9C1 and 9B2 TCRs were synthesized (Integrated DNA Technologies) and cloned
into the pET30 vector (Novagen). The 9C1 and 9B2 TCR mutants were produced
by overlapping extension PCR with primers that included the desired mutations.
The 9C1 and 9B2 wild-type and mutants TCRs were transformed into E. coli BL21
(DE3) pLysS for expression and produced as inclusion bodies. Both TCRs were
subsequently produced by oxidative refolding as previously described and puriﬁed
by size exclusion chromatography, hydrophobic interaction chromatography and
anion exchange chromatography51. Soluble human CD1d either with or without a
C terminus BirA biotin ligase tag, along with b2-microglobulin, or mouse CD1d
and b2-microglobulin, were cloned into pFastBac Dual (Life Technologies) and
expressed by baculovirus infection of High Five insect cell lines as previously
described51,52. CD1d was puriﬁed by immobilized metal afﬁnity chromatography
followed by size exclusion chromatography using gel ﬁltration (GE Healthcare).
Structure determination and reﬁnement. The 9C1 TCR-CD1d–a-GalCer
and 9B2 TCR-CD1d–a-GalCer complex crystals were obtained in 9–10% PEG
6000/0.1M MES pH 6.0/4% ethylene glycol and 18% PEG 8000/0.1M CHES pH
9.5, respectively. The 9C1 and 9B2 complex crystals were ﬂash-frozen and data
were collected at the MX2 beamline (Australian Synchrotron) to 2.5 Å and 3.1 Å
resolution, respectively. Crystals of the 9C1 TCR were obtained in 20% PEG
3000/0.2M Na acetate/0.1M Tris-HCl pH 7.0 and data were collected at the
MX1 beamline (Australian Synchrotron) to 1.4 Å resolution. All the data were
processed with the programme MOSFLM and were scaled with the CCP4 suite53.
The 9C1 and 9B2 complex crystals belonged to the C2 and P212121 space groups,
respectively, and the unit cells were consistent with one complex in the asymmetric
unit for both complexes. The 9C1 TCR crystal belonged to the P21 space group.
For the 9C1 TCR, molecular replacement was carried out with the programme
PHASER54, using the NKT15 TCR (PDB code: 2PO6). For the 9C1-CD1d–a-
GalCer, a molecular replacement solution was found with the programme
PHASER54 using the structures of human CD1d without the lipid (pdb code:
2PO6) and the reﬁned 9C1 TCR minus the CDR loops as two separate search
ensembles. The 9B2 TCR-CD1d–a-GalCer crystal structure was also determined by
molecular replacement (PHASER) and using human CD1d without the lipid (PDB
code: 2PO6) and the NKT15 TCR minus the CDR loops as two separate search
ensembles. For the three crystal structures, an initial run of rigid body reﬁnement
was performed with the reﬁnement programme BUSTER 2.10 (ref. 55) and the
CDR loops of the TCRs were subsequently rebuilt using the programme COOT56.
The density of the a-GalCer headgroup was unambiguous for both complexes.
After iterative model building with COOT and reﬁnement with BUSTER 2.10, the
9C1 and 9B2 complex structures reﬁnement led to an R/R-free (%) of 20/24.9 and
19.5/25.5, respectively, while an R/R-free (%) of 19.6/21.7 was obtained for the 9C1
TCR structure. The quality of the three structures was conﬁrmed at the Research
Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and
Deposition Services website and using the server Molprobity57. All presentations of
molecular graphics were created with the PyMOL molecular visualization system58.
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